Relationship between immune‐related adverse events and treatment effectiveness in extensive disease small cell lung cancer
Thoracic Cancer · 2023
DOI: 10.1111/1759-7714.15010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Keiki Yokoo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Teine Keijinkai Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
This study aimed to assess the relationship between immune response adverse events (irAEs) and treatment efficacy in patients with extensive disease small cell lung cancer (ED‐SCLC).
Methods
We retrospectively evaluated the clinical effects in 40 ED‐SCLC patients who had received immune‐checkpoint inhibitors (ICIs), platinum agents, and etoposide between September 2019 and September 2021. We identified and compared patients belonging to two groups: irAE and non‐irAE.
Results
Fifteen patients experienced irAEs, and 25 did not. The median progression‐free survival in patients with irAE was longer than that in patients without irAE (12.6 months [95% CI: 6.3–19.3 months] vs. 7.2 months [95% CI: 5.8–7.9 months], p = 0.0108). However, the median overall survival (OS) was similar between irAE and non‐irAE groups (27.6 months [95% CI: 15.4–NA] vs. 24.9 months [95% CI: 13.7–NA], p = 0.268). Seven (46.7%) in the irAE group and 20 (80%) in the non‐irAE group received sequential therapy. The median OS was prolonged in patients who received first‐ and second‐line therapy than in those who received first‐line therapy alone (27.6 months [95% CI: 19.2–NA] vs. 6.6 months [95% CI: 0.3–NA], p = 0.053). Grade ≧ 3 irAEs occurred in five (12.5%) patients. Among them, grade 5 irAEs were observed in two patients, including exacerbation of polymyositis and pulmonary arterial embolism.
Conclusion
In this study, the development of irAEs did not affect OS in patients with ED‐SCLC who received platinum‐based agents, etoposide, or ICI therapy. We determined that managing irAEs and administering first‐ and second‐line therapies could contribute to prolonged OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Teine Keijinkai Hospital, Sapporo, Japan.
- Department of Respiratory Medicine, Kushiro City General Hospital, Kushiro, Japan.
- Department of Respiratory Medicine, Hakodate Goryoukaku Hospital, Hakodate, Japan.
- Department of Pulmonary Medicine, Steel Memorial Muroran Hospital, Muroran, Japan.
- Nagasaki University Hospital Infectious Diseases Experts Training Center, Nagasaki, Japan.
ORCID-Profile: Keiki Yokoo
Zitieren
APA
Yokoo, K., Kitamura, Y., Suzuki, K., Morikawa, K., Sawai, T., Honda, H., Kudo, S., & Yamada, G. (2023). Relationship between immune‐related adverse events and treatment effectiveness in extensive disease small cell lung cancer. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15010
Vancouver
Yokoo K, Kitamura Y, Suzuki K, Morikawa K, Sawai T, Honda H, et al. Relationship between immune‐related adverse events and treatment effectiveness in extensive disease small cell lung cancer. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15010
BibTeX
@article{Yokoo2023,
author = {Yokoo, Keiki and Kitamura, Yauo and Suzuki, Keito and Morikawa, Kohei and Sawai, Takeo and Honda, Hiroyuki and Kudo, Sayaka and Yamada, Gen},
title = {Relationship between immune‐related adverse events and treatment effectiveness in extensive disease small cell lung cancer},
journal = {Thoracic Cancer},
year = {2023},
doi = {10.1111/1759-7714.15010}
}
EUVIMED